Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer

Publication Date: December 21, 2021
Last Updated: March 14, 2022

Recommendations

Patients with HER2-positive breast cancer with pathologic invasive residual disease at surgery following standard preoperative chemotherapy and HER2-targeted therapy should be offered 14 cycles of adjuvant trastuzumab emtansine (T-DM1) unless there is disease recurrence or unmanageable toxicity. (EB, B, H, S)
1048203

Overview

Title

Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer

Authoring Organization